111, Inc. (NASDAQ:YI) Short Interest Down 33.3% in April

111, Inc. (NASDAQ:YI - Get Free Report) saw a large decline in short interest in April. As of April 15th, there was short interest totalling 2,000 shares, a decline of 33.3% from the March 31st total of 3,000 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 34,400 shares, the short-interest ratio is currently 0.1 days.

111 Trading Up 1.8 %

YI traded up $0.15 on Friday, reaching $8.40. The stock had a trading volume of 7,515 shares, compared to its average volume of 23,462. The company has a market capitalization of $71.84 million, a price-to-earnings ratio of -2.10 and a beta of 0.57. 111 has a fifty-two week low of $4.15 and a fifty-two week high of $14.10. The firm has a 50-day moving average of $8.36 and a 200-day moving average of $7.40.

111 (NASDAQ:YI - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter. The company had revenue of $527.14 million for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a "sell (e+)" rating on shares of 111 in a research note on Thursday, April 24th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in YI. FIL Ltd bought a new stake in shares of 111 during the 4th quarter valued at about $450,000. Napean Trading & Investment Co Singapore PTE Ltd acquired a new stake in shares of 111 during the 4th quarter worth approximately $245,000. Finally, JPMorgan Chase & Co. increased its stake in shares of 111 by 43,619.9% in the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock valued at $191,000 after acquiring an additional 305,339 shares in the last quarter. Institutional investors own 21.32% of the company's stock.

111 Company Profile

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.